Beneficial effect of a platelet-activating factor antagonist, WEB 2086, on endotoxin-induced lung injury
- 1 January 1990
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 258 (1) , H153-H158
- https://doi.org/10.1152/ajpheart.1990.258.1.h153
Abstract
We tested the hypothesis that platelet-activating factor plays an important role in promoting endotoxin-induced lung injury by studying the effect of WEB 2086, a specific platelet-activating factor receptor antagonist, on lung vascular leak in endotoxin-treated rats. Intraperitoneal injection of Salmonella enteritidis endotoxin (2 mg/kg) increased the extravascular leakage of 125I-labeled albumin in perfused lungs as 30 min, 2 h, 6 h, and 48 h. Treatment with WEB 2086 (10 mg/kg ip) either 20 min before or 30 min after endotoxin injection significantly reduced lung injury at 2 h after endotoxin (leak index: control 0.74 .+-. 0.03, endotoxin 1.79 .+-. 0.14, endotoxin + pretreated WEB 1.23 .+-. 0.09, endotoxin + posttreated WEB 1.21 .+-. 0.13). In addition, posttreatment with WEB 2086 starting at 90 min after endotoxin injection markedly reduced lung leak at 6 h (control 0.74 .+-. 0.03, endotoxin 1.29 .+-. 0.14, endotoxin + WEB 0.71 .+-. 0.06). The protective effect of WEB 2086 was not the result of cyclooxygenase blockade because the release of thromboxane B2 by endotoxin-treated lungs was not affected by WEB 2086. Furthermore, neither pretreatment nor posttreatment with WEB 2086 significantly reduced the endotoxin-induced increase in plasma glutathione disulfide, a marker of in vivo oxidative stress. In rats given a lethal dose of endotoxin (20 mg/kg ip), posttreatment with WEB 2086, starting at 2 h after endotoxin, significantly improved survival compared with vehicle treatment. We conclude that WEB 2086 ameliorated endotoxin-induced lung injury without reducing oxidative stress in the rat and suggest that blockade of platelet-activating factor receptor may be an important therapeutic consideration is sepsis-induced acute lung vascular injury.This publication has 20 references indexed in Scilit:
- Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats.Journal of Clinical Investigation, 1987
- Biological properties of the antagonist SRI 63–441 in the PAF and endotoxin models of hypotension in the rat and dogImmunopharmacology, 1987
- Protective effect of WEB 2086, a novel antagonist of platelet activating factor, in endotoxin shockEuropean Journal of Pharmacology, 1987
- Platelet-activating factor increases lung vascular permeability to proteinJournal of Applied Physiology, 1986
- Interference of the PAF-acether antagonist BN 52021 with endotoxin-induced hypotension in the guinea-pigProstaglandins, 1986
- Platelet activating factor-induced ischemic bowel necrosis: The effect of PAF antagonistsEuropean Journal of Pharmacology, 1986
- Platelet activating factor (PAF) involvement in endotoxin-induced hypotension in rats. studies with paf-receptor antagonist kadsurenoneBiochemical and Biophysical Research Communications, 1985
- Is platelet activating factor (PAF) a mediator of endotoxin shock?European Journal of Pharmacology, 1985
- Platelet-Activating Factor Raises Airway and Vascular Pressures and Induces Edema in Lungs Perfused with Platelet-Free Solution1–3American Review of Respiratory Disease, 1984
- Activation of human neutrophils with 1-O-hexadecyl/octadecyl-2-acetyl-sn-glycerol-3-phosphorylcholine (platelet activating factor).The Journal of Immunology, 1981